-
EBMT Global Perspective | Professor Francesca Ferrua: Breakthroughs in Autologous Hematopoietic Stem Cell Gene Therapy for WAS—From Concept to Clinical Practice
Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by thrombocytopenia, eczema, and recurrent infections, posing a serious threat to affected children. While allogeneic hematopoietic stem cell transplantation (HSCT) can be curative, it is limited by donor availability, the risk of graft-versus-host disease (GVHD), and conditioning-related toxicity.
-
EBMT Global Perspective | Professor Annalisa Ruggeri: Cord Blood Transplantation—From Established Platform to Frontier Therapeutic Modality
Cord blood transplantation (CBT), an important modality within hematopoietic stem cell transplantation, has faced increasing competition in recent years from alternative donor strategies such as haploidentical transplantation. As a result, the field is undergoing a period of reassessment and transformation. Nevertheless, CBT retains irreplaceable value in selected patient populations, while its potential applications in cell…
-
Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference
As a bellwether for innovation in oncology drug therapy, the evolution of lymphoma treatment reflects the broader trajectory of modernization in Chinese oncology. From the introduction of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in 1992—laying the foundation for chemotherapy—to successive breakthroughs in targeted therapy, immunotherapy, and cellular therapy, China’s lymphoma care has undergone 35 years…
-
Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration
From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Symposium, was held in Changsha. During the meeting, Professor Yajing Xu, Executive Chair and Director of Hematology at Xiangya Hospital, Central…
-
AACR China Voice | Qilu Pharmaceutical Showcases Multiple Innovative Breakthroughs at AACR, Driving Global Advances in Oncology Through Originative Innovation
From April 17 to 22, 2026, the Annual Meeting of the American Association for Cancer Research—one of the most influential events in global oncology—was held. At this premier scientific forum, the R&D team of Qilu Pharmaceutical presented a series of independently developed innovative research achievements spanning cutting-edge fields such as antibody–drug conjugates (ADCs), bispecific and…
-
AACR China Voice | Professor Tao Zhu: First-in-Human Study of CLDN6 ADC QLS5132 Demonstrates Promising Efficacy and Safety, Opening New Directions for Platinum-Resistant Ovarian Cancer
Platinum-resistant recurrent ovarian cancer (PROC) remains a major clinical challenge, characterized by poor overall prognosis, limited effective treatment options, high unmet medical need, and suboptimal safety profiles. Innovative treatment strategies are urgently needed.
Connecting Medical Expertise through Media